RNA vaccine against SARS-CoV-2 variants

US11872280B2 · kind B2 · utility

Assignees

• CureVac SE · DE
• GLAXOSMITHKLINE BIOLOGICALS SA · BE

Inventors

• Nicole ROTH · Tübingen, DE
• Diego Moreno · Tübingen, DE
• Hans Wolfgang GROßE · Tübingen, DE
• Dominik VAHRENHORST · Tübingen, DE
• Susanne RAUCH · Tübingen, DE

Key dates

• Filing date: May 31, 2022
• Grant date: Jan 16, 2024
• Expiry date: May 31, 2042

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2770/20071
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to a nucleic acid suitable for use in treatment or prophylaxis of an infection with a coronavirus, preferably with a Coronavirus SARS-CoV-2, or a disorder related to such an infection, preferably COVID-19. The present invention is also directed to compositions, polypeptides, and vaccines. The compositions and vaccines preferably comprise at least one of said nucleic acid sequences, preferably nucleic acid sequences in association a lipid nanoparticle (LNP). The invention is also directed to first and second medical uses of the nucleic acid, the composition, the polypeptide, the combination, the vaccine, and the kit, and to methods of treating or preventing a coronavirus infection, preferably a Coronavirus infection.